CRISPR QC, a San Diego, CA-based biotechnology startup, secured funding from Xcellerant Ventures in its ongoing Series A funding round.
The amount of the deal was not disclosed.
The backing from Xcellerant Ventures will fund further developments in the CRISPR Analytics Platform.
Led by Ross Bundy, CRISPR QC leverages its analytics platform to provide comprehensive measurements and analysis around CRISPR activity, enabling scientists and researchers to optimize gene editing outcomes and ensure the highest levels of quality control. The platform is built on the company’s proprietary CRISPR-Chip technology, which allows for direct, real-time measurement of CRISPR activity.
As the company’s staff grows, the company is set to open its satellite office in Sedona, Arizona.
FinSMEs
05/01/2023